Analysts Offer Predictions for Actinium Pharmaceuticals, Inc.’s Q2 2024 Earnings (NYSEAMERICAN:ATNM)

Actinium Pharmaceuticals, Inc. (NYSEAMERICAN:ATNM) – Research analysts at B. Riley issued their Q2 2024 earnings per share estimates for Actinium Pharmaceuticals in a research report issued to clients and investors on Wednesday, May 1st. B. Riley analyst Y. Zhi anticipates that the biotechnology company will post earnings per share of ($0.58) for the quarter. The consensus estimate for Actinium Pharmaceuticals’ current full-year earnings is ($1.48) per share. B. Riley also issued estimates for Actinium Pharmaceuticals’ Q3 2024 earnings at ($0.53) EPS, Q4 2024 earnings at ($0.37) EPS, FY2024 earnings at ($1.49) EPS and FY2025 earnings at ($0.45) EPS.

A number of other equities research analysts also recently issued reports on the stock. Maxim Group upped their price target on shares of Actinium Pharmaceuticals from $20.00 to $30.00 and gave the company a “buy” rating in a research note on Tuesday, March 19th. StockNews.com upgraded shares of Actinium Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Sunday. HC Wainwright reiterated a “buy” rating and issued a $50.00 price target on shares of Actinium Pharmaceuticals in a research report on Monday, April 29th. Finally, Cantor Fitzgerald restated an “overweight” rating and set a $21.00 price objective on shares of Actinium Pharmaceuticals in a research report on Tuesday, April 30th. One analyst has rated the stock with a hold rating and five have given a buy rating to the company’s stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $25.72.

Actinium Pharmaceuticals Stock Performance

Shares of ATNM stock opened at $8.84 on Monday. Actinium Pharmaceuticals has a 52 week low of $4.00 and a 52 week high of $9.86. The firm has a market capitalization of $263.26 million, a price-to-earnings ratio of -5.17 and a beta of 0.08.

Actinium Pharmaceuticals (NYSEAMERICAN:ATNM) last posted its quarterly earnings results on Friday, March 29th. The biotechnology company reported ($0.33) EPS for the quarter, topping analysts’ consensus estimates of ($0.54) by $0.21. The business had revenue of $0.08 million during the quarter.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently made changes to their positions in the stock. Brandywine Global Investment Management LLC acquired a new stake in Actinium Pharmaceuticals in the third quarter valued at approximately $1,033,000. Creative Financial Designs Inc. ADV boosted its position in shares of Actinium Pharmaceuticals by 19.1% in the 4th quarter. Creative Financial Designs Inc. ADV now owns 19,800 shares of the biotechnology company’s stock worth $101,000 after purchasing an additional 3,175 shares in the last quarter. Finally, Sanders Morris Harris LLC acquired a new stake in shares of Actinium Pharmaceuticals in the 1st quarter worth $78,000. 27.50% of the stock is currently owned by hedge funds and other institutional investors.

About Actinium Pharmaceuticals

Actinium Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops targeted radiotherapies to deliver cancer-killing radiation to treat patients with high unmet medical needs. Its lead product candidate, I-131 apamistamab (Iomab-B) that is in a pivotal Phase III clinical trial for elderly relapsed or refractory acute myeloid leukemia trial for bone marrow transplant conditioning; and a Phase I study with a CD19- targeted CAR T-cell therapy with memorial sloan kettering cancer center.